Effect of aliximab combined with rosuvastatin on lipid-lowering therapy in patients with coronary heart disease and their influence on inflammatory factors,cardiac function and prognosis
Effect of aliximab combined with rosuvastatin on lipid-lowering therapy in patients with coronary heart disease and their influence on inflammatory factors,cardiac function and prognosis
Objective To investigate the effect of alixiumab combined with rosuvastatin on lipid-lowering therapy in patients with coro-nary heart disease and their influence on inflammatory factors,cardiac function and prognosis.Methods A total of 82 patients with coronary heart disease admitted to Baoji Central Hospital from January 2022 to December 2023 were prospectively selected as the study subjects.According to the random number table method,they were divided into the observation group and the control group,41 cases in each group.The control group was treated with rosuvastatin,and the observation group was treated with alixiyumab combined with rosuvastatin.Both groups were treated for 6 months.The blood lipid[total cholesterol,triglycerides and low density lipoprotein cholesterol(LDL-C)]levels,serum inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)]and cardiac function indexes[left ventricular end-diastolic diam-eter(LVEDD),left ventricular ejection fraction(LVEF),serum N-terminal B-type natriuretic peptide precursor(NT-proBNP)]before treatment and 6 months after treatment were compared between the two groups.The major adverse cardiovascular events(MACE)incidence and adverse reactions between the two groups were compared.Results At 6 months after treatment,the levels of total cholesterol,triglyceride and LDL-C in the two groups were significantly lower than those before treatment,and the levels of total cholesterol,triglyceride and LDL-C in the observation group were(3.21±0.75),(1.39±0.51)and(1.71±0.55)mmol/L,respectively,which were lower than those in the control group[(3.78±0.91),(1.78±0.57)and(2.17±0.51)mmol/L],the differences were statistically significant(P＜0.05).At 6 months after treatment,the levels of hs-CRP and IL-6 in the two groups were significantly lower than those before treatment,and the levels of hs-CRP and IL-6 in the observation group were(5.17±1.34)mg/L and(7.52±1.67)ng/L,respectively,which were lower than those in the control group[(7.46±1.67)mg/L,(9.11±1.87)ng/L],the differences were statistically significant(P＜0.05).After 6 months of treatment,the LVEDD and serum NT-proBNP levels were significantly lower than those before treatment and the LVEF of the two groups was significantly higher than that before treatment.The LVEDD and serum NT-proBNP levels were(52.78±4.49)mm and(464.36±136.58)ng/L,respectively.They were lower than those in the control group[(54.32±4.61)mm,(625.36±201.68)ng/L],the LVEF of the observation group was(56.17±4.25)％,which was significantly higher than that of the control group[(54.29±4.07)％],and the differences were statistically sig-nificant(P＜0.05).The incidence of MACE in the observation group was 24.39％,which was lower than that in the control group(7.32％),and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(12.20％vs.7.32％)(P＞0.05).Conclusion Alicyumab combined with rosuvastatin lipid-lower-ing therapy in patients with coronary heart disease can more effectively reduce blood lipid levels,reduce inflammation,improve cardiac function,reduce the incidence of MACE,and has good safety.
维普
万方数据